Skip to content
21 | 09 | 2024
—clinical

LightWave I Clinical Trial Confirms Safety and Short-term Efficacy of Light Modulation™ LLLT (PBM) on eye-light® for dAMD

 

Espansione Group is thrilled to announce the release of the 6-Month milestone publication of the DRUSEN Study, part of the greater LightWave I research effort — a multicentric clinical trial aimed at studying the impact of LM™ LLLT on dAMD Patients. 

The study has been published in the September Issue of Springer’s Ophthalmology & Therapy Journal. In the study, part of a longer longitudinal, double-masked multicentric trial effort, the safety, tolerability, and short-term efficacy of Light Modulation™ Low-Level Light Therapy (LM™ LLLT) for patients with Dry Age-Related Macular Degeneration (dAMD) has been proven.

Whilst a total of over 200 patients were enrolled within LightWave I, 152 eyes from 76 patients were admitted into the sample.

Given the significant impact on quality of life and the related social costs of AMD, diagnosing, monitoring, and treating the disease are poised to become major challenges for the global ophthalmology community in the coming years. Research efforts and innovative therapeutic approaches such as LM™ LLLT (PBM) are focusing on slowing the progression of the disease and preventing the advanced stages, characterized by either outer retinal and RPE atrophy, or development of wet AMD.

Prof. Enrico Borrelli (MD, PhD), lead investigator of the study from University of Turin, noted that, “The LightWave I trial and the DRUSEN study represent a major milestone deepening our understanding of light therapy’s impact in the management of degenerative retinal conditions such as dry AMD.”

Reporting directly from the recent publication:

  • Changes in best‐corrected visual acuity (BCVA) from baseline to month 4 differed significantly between the sham and PBM‐treated groups, favoring the latter, with a higher pro‐ portion achieving a gain of five or more letters post‐treatment (8.9% vs. 20.3%, respectively; p=0.043).
  • The study also found a statistically significant dispar‐ ity in mean drusen volume changes from baseline to month 4 between the groups in favor of patients treated with PBM (p=0.013).

Access the full-length publication via the Bibliography section on our website.

 

About Espansione Group

Espansione Group is a pioneer in the medtech industry, on a mission to develop and market innovative, non-invasive solutions for prevention and management of conditions in ophthalmology and beyond.  

The company’s certified medical solutions leverage proprietary technologies such as Light Modulation™ Low-level Light Therapy (LM™ LLLT) photobiomodulation (PBM), with an ambition to redefine standards of care by expanding on their applications, with a constant commitment to science, research and development, and customer excellence.

Strategic partnerships with the industry, a strong commitment to scientific excellence and a will to shape the future have enabled Espansione Group’s advanced medical technologies to be present in over 50 countries, serving thousands healthcare providers worldwide.

For more information, visit www.espansionegroup.it

 

Espansione Group Press Office
press@espansione.it 
© 2024 Espansione Group, All Rights Reserved
Posted on September 21st, 2024 in Newsroom

 

Get Started Now
Get in touch to find out how you can benefit from the Espansione Ecosystem of Technologies and Solutions.

In compliance with current regulations, let us know which audience you belong to:

You must fill in the form to download the file.

I want to be updated about Espansione products and services

This field is required.
This field is required.
This field is required.
A valid email address is required.
This field is required.
This field is required.
I have read the privacy policy and the terms and conditions of the site
This field is required.
I want to be updated about Espansione products and services. You can unsubscribe at any time, by using the “unsubscribe” feature at the bottom of any communication you receive.

Thank you for contacting us.